Atea Pharmaceuticals is a clinical-stage biopharmaceutical company focused on oral antiviral therapies for serious viral infections. Its lead program combines bemnifosbuvir, a nucleotide polymerase inhibitor, with ruzasvir, an NS5A inhibitor, in late-stage development for hepatitis C. The company also advances earlier antiviral candidates and builds on a nucleoside/nucleotide chemistry platform rather than commercialized marketed products today.
| Quarter | Revenue | YoY % | Earnings | YoY % |
|---|---|---|---|---|
| Q1 2025 | 0 | — | -34.3 | — |
| Q2 2025 | 0 | — | -37.2 | — |
| Q3 2025 | 0 | — | -42 | — |
| Q4 2025 | 0 | — | -44.9 | — |
| Q1 2026 | 0 | — | -45.4 | — |
| Q2 2026 | 0 | — | -32.9 | — |
All markets — KeepWinning global stock screener
Other companies on Nasdaq: Innovative Aerosystems, Inc. (IA), Rezolute, Inc. (RZLT), Bit Digital, Inc. (BTBT), Artesian Resources Corporation (ARTNA), Daedalus Special Acquisition Corp. (DSAC), Flexsteel Industries, Inc. (FLXS)